CDSCO approves Zytorvi (toripalimab) for first-line treatment of advanced ESCC

Dr. Reddy’s Laboratories received CDSCO/DCGI approval to use Zytorvi (toripalimab) for treating unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). The approval is for use in combination with cisplatin and paclitaxel as a first-line treatment for adult patients, adding a second approved indication in India beyond nasopharyngeal carcinoma.